|
|
 Previous Article | Table of Contents | Next Article 
In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia
G.J.L. Kaspers,
A.J.P. Veerman,
R. Pieters,
C.H. Van Zantwijk,
L.A. Smets,
E.R. Van Wering, and
A. Van Der Does-Van Den Berg
From the Department of Pediatrics, Free University Hospital, Amsterdam; Dutch Childhood Leukemia Study Group, The Hague; and the Netherlands Cancer Institute, Amsterdam, The Netherlands.
As an important determinant of the response to chemotherapy, measurements of cellular drug resistance may provide prognostically significant information, which could be useful for optimal risk-group stratification. The objective of this report is to determine the relation between in vitro resistance to 12 drugs, measured with the colorimetric methyl-thiazol-tetrazolium (MTT) assay, and long-term clinical response to chemotherapy in 152 children with newly diagnosed acute lymphoblastic leukemia. At risk-group stratified analyses, in vitro resistance to prednisolone, L-asparaginase, and vincristine were each significantly (P < .01) related to the probability of disease-free survival (pDFS) after combination chemotherapy. The combination of data for prednisolone, L-asparaginase, and vincristine provided a drug-resistance profile with prognostic independent significance superior to that of any single drug or any other factor. The 3-years pDFS was 100% for the group with the most sensitive profile, 20% of all patients, 84% (SE 6%) for the group with an intermediately sensitive profile, 40% of all patients, and 43% (SE 8%) for the remaining group with the most resistant profile (P < .001). In conclusion, the extent of in vitro cellular resistance to prednisolone, L-asparaginase, and vincristine, measured using the MTT assay, was significantly related to the clinical response to combination chemotherapy. Treatment failure in newly diagnosed childhood ALL can be predicted based on cellular drug resistance data.
Blood, Vol. 90 No. 7 (October 1), 1997:
pp. 2723-2729
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. W. Behan, J. P. Yun, M. P. Proektor, E. A. Ehsanipour, A. Arutyunyan, A. S. Moses, V. I. Avramis, S. G. Louie, A. Butturini, N. Heisterkamp, et al.
Adipocytes Impair Leukemia Treatment in Mice
Cancer Res.,
October 1, 2009;
69(19):
7867 - 7874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Pottier, W. Yang, M. Assem, J. C. Panetta, D. Pei, S. W. Paugh, C. Cheng, M. L. Den Boer, M. V. Relling, R. Pieters, et al.
The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia
J Natl Cancer Inst,
December 17, 2008;
100(24):
1792 - 1803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Ong, N. L. M. Liem, M. A. Schmid, N. M. Verrills, R. A. Papa, G. M. Marshall, K. L. MacKenzie, M. Kavallaris, and R. B. Lock
A Role for Altered Microtubule Polymer Levels in Vincristine Resistance of Childhood Acute Lymphoblastic Leukemia Xenografts
J. Pharmacol. Exp. Ther.,
February 1, 2008;
324(2):
434 - 442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kang, Y. H. Kang, B. Szymanska, U. Wilczynska-Kalak, M. A. Sheard, T. M. Harned, R. B. Lock, and C. P. Reynolds
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Blood,
September 15, 2007;
110(6):
2057 - 2066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Choi, Y. K. Hwang, K. W. Sung, S. H. Lee, K. H. Yoo, H. L. Jung, H. H. Koo, H.-J. Kim, H. J. Kang, H. Y. Shin, et al.
Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia
Blood,
January 15, 2007;
109(2):
471 - 477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, et al.
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.
Science,
September 29, 2006;
313(5795):
1929 - 1935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Meyer, L. Karawajew, M. Schrappe, W.-D. Ludwig, K.-M. Debatin, and K. Stahnke
Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL
Blood,
June 1, 2006;
107(11):
4524 - 4531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Appel, M. L. den Boer, J. P. P. Meijerink, A. J. P. Veerman, N. C. M. Reniers, and R. Pieters
Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia
Blood,
June 1, 2006;
107(11):
4244 - 4249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Holleman, M. L. den Boer, R. X. de Menezes, M. H. Cheok, C. Cheng, K. M. Kazemier, G. E. Janka-Schaub, U. Gobel, U. B. Graubner, W. E. Evans, et al.
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia
Blood,
January 15, 2006;
107(2):
769 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Holleman, M. L. d. Boer, K. M. Kazemier, H. B. Beverloo, A. R. M. von Bergh, G. E. Janka-Schaub, and R. Pieters
Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia
Blood,
September 1, 2005;
106(5):
1817 - 1823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. G. Stams, M. L. den Boer, A. Holleman, I. M. Appel, H. B. Beverloo, E. R. van Wering, G. E. Janka-Schaub, W. E. Evans, and R. Pieters
Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia
Blood,
June 1, 2005;
105(11):
4223 - 4225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Fine, G. J.L. Kaspers, M. Ho, A. H. Loonen, and L. M. Boxer
A Genome-Wide View of the In vitro Response to L-Asparaginase in Acute Lymphoblastic Leukemia
Cancer Res.,
January 1, 2005;
65(1):
291 - 299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Holleman, M. H. Cheok, M. L. den Boer, W. Yang, A. J.P. Veerman, K. M. Kazemier, D. Pei, C. Cheng, C.-H. Pui, M. V. Relling, et al.
Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
N. Engl. J. Med.,
August 5, 2004;
351(6):
533 - 542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Winick, W. L. Carroll, and S. P. Hunger
Childhood Leukemia -- New Advances and Challenges
N. Engl. J. Med.,
August 5, 2004;
351(6):
601 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. M. Liem, R. A. Papa, C. G. Milross, M. A. Schmid, M. Tajbakhsh, S. Choi, C. D. Ramirez, A. M. Rice, M. Haber, M. D. Norris, et al.
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies
Blood,
May 15, 2004;
103(10):
3905 - 3914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Zwaan, S. Meshinchi, J. P. Radich, A. J. P. Veerman, D. R. Huismans, L. Munske, M. Podleschny, K. Hahlen, R. Pieters, M. Zimmermann, et al.
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
Blood,
October 1, 2003;
102(7):
2387 - 2394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.L. Den Boer, D.O. Harms, R. Pieters, K.M. Kazemier, U. Gobel, D. Korholz, U. Graubner, R.J. Haas, N. Jorch, H.J. Spaar, et al.
Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
September 1, 2003;
21(17):
3262 - 3268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. G. Stams, M. L. den Boer, H. B. Beverloo, J. P. P. Meijerink, R. L. Stigter, E. R. van Wering, G. E. Janka-Schaub, R. Slater, and R. Pieters
Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL
Blood,
April 1, 2003;
101(7):
2743 - 2747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Zwaan, G. J. L. Kaspers, R. Pieters, K. Hahlen, D. R. Huismans, M. Zimmermann, J. Harbott, R. M. Slater, U. Creutzig, and A. J. P. Veerman
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities
Blood,
October 16, 2002;
100(9):
3352 - 3360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Coustan-Smith, J. Sancho, F. G. Behm, M. L. Hancock, B. I. Razzouk, R. C. Ribeiro, G. K. Rivera, J. E. Rubnitz, J. T. Sandlund, C.-H. Pui, et al.
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
Blood,
June 17, 2002;
100(1):
52 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Lock, N. Liem, M. L. Farnsworth, C. G. Milross, C. Xue, M. Tajbakhsh, M. Haber, M. D. Norris, G. M. Marshall, and A. M. Rice
The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse
Blood,
May 13, 2002;
99(11):
4100 - 4108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Wuchter, V. Ruppert, M. Schrappe, B. Dorken, W.-D. Ludwig, and L. Karawajew
In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia
Blood,
May 13, 2002;
99(11):
4109 - 4115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Zwaan, G. J. L. Kaspers, R. Pieters, K. Hahlen, G. E. Janka-Schaub, C. H. van Zantwijk, D. R. Huismans, E. de Vries, M. G. Rots, G. J. Peters, et al.
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
Blood,
January 1, 2002;
99(1):
245 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Kearns, R. Pieters, M. M. A. Rottier, A. D. J. Pearson, and A. G. Hall
Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia
Blood,
January 15, 2001;
97(2):
393 - 398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, J.-Y. Perrot, G. Simonin, M. Baudard, and J.-P. Marie
JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia
Blood,
January 15, 2001;
97(2):
502 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Coustan-Smith, J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm, S. C. Raimondi, J. T. Sandlund, G. K. Rivera, J. E. Rubnitz, R. C. Ribeiro, et al.
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
Blood,
October 15, 2000;
96(8):
2691 - 2696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Zwaan, G.-J. L. Kaspers, R. Pieters, N. L. R.-V. Woerden, M. L. den Boer, R. Wunsche, M. M. A. Rottier, K. Hahlen, E. R. van Wering, G. E. Janka-Schaub, et al.
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia
Blood,
October 15, 2000;
96(8):
2879 - 2886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, J.-Y. Perrot, M. Baudard, A. Cordier, R. Lautier, G. Simonin, R. Zittoun, N. Casadevall, and J.-P. Marie
The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score
Blood,
August 1, 2000;
96(3):
870 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. R.-v. Woerden, R. Pieters, A. H. Loonen, I. Hubeek, E. van Drunen, H. B. Beverloo, R. M. Slater, J. Harbott, J. Seyfarth, E. R. van Wering, et al.
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
Blood,
August 1, 2000;
96(3):
1094 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Karawajew, V. Ruppert, C. Wuchter, A. Kosser, M. Schrappe, B. Dorken, and W.-D. Ludwig
Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia
Blood,
July 1, 2000;
96(1):
297 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schrappe, A. Reiter, W.-D. Ludwig, J. Harbott, M. Zimmermann, W. Hiddemann, C. Niemeyer, G. Henze, A. Feldges, F. Zintl, et al.
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90
Blood,
June 1, 2000;
95(11):
3310 - 3322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Liu, P. Sidiropoulos, G. Song, L. J. Pagliari, M. J. Birrer, B. Stein, J. Anrather, and R. M. Pope
TNF-{alpha} Gene Expression in Macrophages: Regulation by NF-{kappa}B Is Independent of c-Jun or C/EBP{beta}
J. Immunol.,
April 15, 2000;
164(8):
4277 - 4285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O B Eden
Therapeutic trials in childhood ALL: what's their future?
J. Clin. Pathol.,
January 1, 2000;
53(1):
55 - 59.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.A. Kamps, J.P.M. Bokkerink, K. Hahlen, J. Hermans, H. Riehm, H. Gadner, M. Schrappe, R. Slater, E. v. d. B.-d. Ruiter, L.A. Smets, et al.
Intensive Treatment of Children With Acute Lymphoblastic Leukemia According to ALL-BFM-86 Without Cranial Radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991)
Blood,
August 15, 1999;
94(4):
1226 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie
Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia
Blood,
August 1, 1999;
94(3):
1046 - 1056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Rots, R. Pieters, G.-J. L. Kaspers, C. H. van Zantwijk, P. Noordhuis, R. Mauritz, A. J.P. Veerman, G. Jansen, and G. J. Peters
Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay
Blood,
February 1, 1999;
93(3):
1067 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui and W. E. Evans
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
August 27, 1998;
339(9):
605 - 615.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.J.L. Kaspers, R. Pieters, C.H. Van Zantwijk, E.R. VanWering, A. Van Der Does-Van Den Berg, and A.J.P. Veerman
Prednisolone Resistance in Childhood Acute Lymphoblastic Leukemia: Vitro-Vivo Correlations and Cross-Resistance to Other Drugs
Blood,
July 1, 1998;
92(1):
259 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, G.J.L. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, et al.
Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia
Blood,
March 15, 1998;
91(6):
2092 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
